IQVIA is the 3rd largest life sciences employer in the UK, we attract an equivalent of £2.2bn of economic impact to the UK. IQVIA operationalised and ran the UK Government COVID Infection Survey for 2.5 years underpinned by the real-world data platform we created within a week of being asked and mobilised 4,000 field workers to undertake testing with 0.5 million participants.
Combining our research, real world and genomics expertise and diagnostics laboratory in Scotland, we played a critical role in contributing to the O’Shaugnessy Review and look forward to becoming a Review Implementation Partner.
Our Clinical Pharmacy teams are supporting ICS leaders and primary care networks to address waiting list challenges and build clinical capacity in General Practice, to support earlier diagnosis and treatment of major conditions, which will have high impact on winter pressures by avoiding unplanned emergency admissions in cardiovascular and respiratory patients. This team is now delivering the National LIPID Management programme, and as a result, our data suggests a significant uptake in use of Inclisirin.
To support and drive key advancements towards improving patient outcomes, IQVIA is at the forefront of unlocking the potential of NHS health data to realise future health improvements for the UK and deliver transformative benefits for the patients of today and tomorrow. IQVIA believes that the value of NHS health data is not in the data per se, but in the clinical decision-making it can inform and as a trusted partner to health systems and providers, we use our extensive data and analytics capabilities to transform health outcomes and deliver pioneering biomedical research within 95% NHS Trusts who use one or more of our services.